Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06026254 · ClinicalTrials.gov registry record · Phase 1
A Rollover Study for Subjects Who Completed Participation in IMSA101-101 Trial
A Phase 1 study of Solid Tumor, Adult, sponsored by ImmuneSensor Therapeutics.
- Active
- Registry status
- Phase 1
- Development phase
- 2
- Enrollment target
- 2
- Study locations
NCT06026254 is a Phase 1 study of Solid Tumor, Adult that is active but no longer recruiting, run by ImmuneSensor Therapeutics. The registered enrollment target is 2 participants, below the 190-participant average among 72 other Solid Tumor, Adult trials with a reported enrollment target (99% lower). The trial reports 2 study locations across 2 states.
The verdict
NCT06026254, a Phase 1 study of Solid Tumor, Adult, is active but no longer recruiting, sponsored by ImmuneSensor Therapeutics.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 2 participants
- Enrollment target
- 2
- Study locations
Study Summary
This is a rollover study from parent protocol IMSA101-101 for adult patients with advanced malignancies that were previously receiving IMSA101 and who would continue to receive benefit with study treatment of IMSA101 in combination with an immune checkpoint inhibitor (ICI).
Conditions Studied
Interventions
- DRUG IMSA101
- DRUG Immune Checkpoint Inhibitor
Study Locations (2)
Arizona
- Honor Health - Scottsdale
California
- UC San Diego Moores Cancer Center - La Jolla
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2 participants |
| Start Date | 2023-09-15 |
| Est. Completion | 2025-09 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06026254
The ClinicalTrials.gov registry entry for NCT06026254 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 2 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 190-participant average among 72 other Solid Tumor, Adult trials with a reported enrollment target (99% lower). The listed sponsor is ImmuneSensor Therapeutics, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Solid Tumor, Adult appearing as the primary indexed condition, and to 2 interventions - of which IMSA101 is the first listed.
NCT06026254 reports 2 study locations spanning 2 distinct geographic areas - top geographies include Arizona, California.
Frequently Asked Questions
What is clinical trial NCT06026254 about?
NCT06026254 is a clinical study titled "A Rollover Study for Subjects Who Completed Participation in IMSA101-101 Trial". This is a rollover study from parent protocol IMSA101-101 for adult patients with advanced malignancies that were previously receiving IMSA101 and who would continue to receive benefit with study treatment of IMSA101 in combination with an immune checkpoint inhibitor (ICI).
What is the current status of trial NCT06026254?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 2 participants. The study started on 2023-09-15. Estimated completion is 2025-09.
What conditions does trial NCT06026254 study?
This clinical trial studies the following conditions: Solid Tumor, Adult.
What interventions are being tested in trial NCT06026254?
The interventions under investigation include: IMSA101 (DRUG), Immune Checkpoint Inhibitor (DRUG).
Who is sponsoring clinical trial NCT06026254?
This trial is sponsored by ImmuneSensor Therapeutics, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06026254 being conducted?
This trial has 2 study locations across Arizona, California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Solid Tumor, Adult
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Study of CRX100 as Monotherapy and in Combination With Pembrolizumab in Patients With Advanced Solid Malignancies
RECRUITING · Phase 1
-
Open-Label, Dose-Escalation With Expansion to Assess the Safety, Tolerability, and PK of TRE-515 in Subjects With Solid Tumors
RECRUITING · Phase 1
-
A Study of BI-1206 in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors
RECRUITING · Phase 1
-
Phase 1 Study to Investigate TCRTs KRAS Mutation in Unresectable, Advanced, and/or Metastatic Solid Tumors
RECRUITING · Phase 1
-
Study Assessing MTD, Safety, Tolerability, PK and Anti-tumor Effects of LNS8801alone and With Pembrolizumab
RECRUITING · Phase 1
-
A Study to Investigate the Safety and Efficacy of NST-628 Oral Tablets in Subjects With Solid Tumors
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.